ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Merus NV

Merus NV (2GH)

41.20
-1.00
( -2.37% )
Updated: 05:24:27
Realtime Data

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
41.20
Bid
41.20
Offer
41.60
Volume
978
39.60 Day's Range 42.80
21.40 52 Week Range 58.50
Previous Close
42.20
Open
42.80
Last Trade
40
@
41.2
Last Trade Time
04:20:15
Average Volume (3m)
127
Financial Volume
-
VWAP
-

2GH Latest News

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC Studie mit Petosemtamab in Kombination mit Pembrolizumab bei 1L...

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m...

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-4.8-10.4347826087464739.624844.22983871DE
4-10.3-2051.551.539.612544.72627361DE
12-4-8.8495575221245.251.539.612747.17167127DE
26-7.8-15.91836734694957.539.615948.54794972DE
5219.287.27272727272258.521.39999917544.36210739DE
15617.473.109243697523.858.51916742.00023485DE
26017.473.109243697523.858.51916742.00023485DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NL8Genesis Ai Corp
0.035 €
(130.26%)
78.41k
2WOWide Open Agriculture Ltd
0.013 €
(85.71%)
35.39k
C0MCCS Abwicklungs AG
0.26 €
(85.71%)
117.98k
KEHChinese People Holdings Co Ltd
0.0045 €
(50.00%)
22.92k
UH7ATennant Minerals NL
0.0095 €
(46.15%)
100k
Y7GBioAge Labs Inc
4.56 €
(-76.00%)
7.77k
4APApollo Minerals Ltd
0.005 €
(-41.18%)
49.2k
HF2Reflex Advanced Materials Corp
0.0136 €
(-38.18%)
11.9k
NJF1Grid Metals Corp
0.016 €
(-37.25%)
2k
47GAGo Metals Corp
0.0202 €
(-36.48%)
3.92k
AXIAtos SE
0.0028 €
(0.00%)
854.18M
D7GNel ASA
0.2689 €
(2.44%)
4.49M
3CPXiaomi Corporation
3.9605 €
(9.74%)
3.59M
9SBSOL Global Investments Corp
0.272 €
(13.33%)
3.43M
RQ0DWave Quantum Inc
4.429 €
(-7.63%)
1.91M

Discussion

View Full Feed
gitreal gitreal 4 minutes ago
I am literally on the edge of my seat on this stock

That's gonna get uncomfortable after awhile. NBRI has gone nowhere for months. They can't even muster much in the way of volume. Billions of shares to sell, and nobody's buying. Are you doing your part? Maybe liquidate your retir
NBRI
FrankMD FrankMD 4 minutes ago
A Regulation S (Reg S) offering is a sale or offer of securities that takes place outside the United States and is exempt from the registration requirements of the Securities Act of 1933. The Securities and Exchange Commission (SEC) created Reg S in 1990 to allow companies to raise capital from non-
HIRU
glenn1919 glenn1919 5 minutes ago
STRM...........................https://stockcharts.com/h-sc/ui?s=STRM&p=W&b=5&g=0&id=p86431144783
STRM
Steady_T Steady_T 5 minutes ago
EMA annual report for 2023.
See pages 51 - 57.

https://www.ema.europa.eu/en/documents/annual-report/2023-annual-report-european-medicines-agency_en.pdf
AVXL
la-tsla-fan la-tsla-fan 5 minutes ago
uk: I know that Mercedes is at level 3 in certain situations, Waymo is at level 4 in parts of Phoenix , San Fransisco and Los Angeles. Tesla's system is thought of as Level 2, BUT for those of us fortunate enough to have it, it is almost a level 5. It does not need special mapping in advance and the
TSLA
StayHumble StayHumble 5 minutes ago
idiot,Kramer NakedShorted💹4Bill+$DBMM shares4Charity?💹✅

Source: TDA 2014 Chart https://investorshub.advfn.com/uimage/uploads/2023/1/29/cpbxb2014_dbmm_trade_data.png Source: https://fintel.io/s/us/dbmm
https://investorshub.advfn.com/uimage/uploads/2023/1/
DBMM
Trinityz1 Trinityz1 5 minutes ago
that was good news today
PioneerPhoenix73 PioneerPhoenix73 5 minutes ago
Thank you to the person that wrote this !

"I would like to express my sincere appreciation to contributors like Entlarvt, Xfund, and PioneerPhonenix73 for their diligent efforts in combating misinformation and conspiracy theories related to Sintx and Tesla within online communities.
TSLA
Golden Cross Golden Cross 5 minutes ago
$ILLR ~ Check out the Triller Brands: Triller, #BKFC, Julius, Amplify.ai,
CLIQZ, CrossHype, FANGAGE and TRILLERTV.

https://youtube.com/watch?v=TKhtsQXbIXo
ILLR
Investor082 Investor082 5 minutes ago
Another acknowledgement there will be no support for Direct trial and big dilution is coming. There will be no non dilutive funding from big pharma, as I have been saying all along.
NWBO
gp22 gp22 6 minutes ago
$VVOS @ $4.40s:..Quietly powering up....History of significant rips on big volume out of of the blue....Lots of eyes on $VVOS.. Microfloat. Cash rich. Recent FDA Approval of only device for Sleep Apnea. Upgraded two weeks ago to $6.00+ Valuation....New Sleep Apnea patent granted last week.
VVOS
Filterthenoise Filterthenoise 6 minutes ago
It's 1:18pm now, some say this is going to 1:19pm shortly but they're just anticipating & hoping. That is what pumpers do. But I know better. Even tho I was proven wrong with FOXO. I still no better.

$RNVA@(#^$(@$($&)!
FOXO RNVA
glenn1919 glenn1919 6 minutes ago
OCFT..................................https://stockcharts.com/h-sc/ui?s=OCFT&p=W&b=5&g=0&id=p86431144783
OCFT
johny1 johny1 6 minutes ago
BTO SPY 606 C @.25
gp22 gp22 6 minutes ago
$VVOS @ $4.40s:..Quietly powering up....History of significant rips on big volume out of of the blue....Lots of eyes on $VVOS.. Microfloat. Cash rich. Recent FDA Approval of only device for Sleep Apnea. Upgraded two weeks ago to $6.00+ Valuation....New Sleep Apnea patent granted last week.
Co
VVOS
Livi1 Livi1 6 minutes ago
If people still can't see where this is headed I can't help them. The small dip earlier this morning was the opportunity.
RDAR
pdmihopefull pdmihopefull 6 minutes ago
Hey NOMODO.....I thought I would not see this kind of drop ☔💧 today...right now we are at 16....I think this might go below my estimate of 15 for today...
HMBL
Golden Cross Golden Cross 6 minutes ago
$ILLR ~ Check out the Triller Brands: Triller, #BKFC, Julius, Amplify.ai,
CLIQZ, CrossHype, FANGAGE and TRILLERTV.

https://youtube.com/watch?v=TKhtsQXbIXo
ILLR
PioneerPhoenix73 PioneerPhoenix73 6 minutes ago
Thank you to the person that wrote this !

"I would like to express my sincere appreciation to contributors like Entlarvt, Xfund, and PioneerPhonenix73 for their diligent efforts in combating misinformation and conspiracy theories related to Sintx and Tesla within online communities.
SINT
ksquared ksquared 7 minutes ago
Donald Trump’s not afraid to make his case to the American people, unlike Joe Biden and Kamala Harris
By Post Editorial Board Published Dec. 9, 2024, 12:16 p.m. ET

Love him or hate him, any sane observer would have to admit that President-elect Donald Trump is utterly unafraid
FLA FLA 7 minutes ago
$BDPTD .105 ^16%
BDPTD
Digit2k Digit2k 7 minutes ago
I signed the releases..is that not enough? can you explain what GSA is pls?
COOP
gfp927z gfp927z 7 minutes ago
>>> Super Micro Wins Key Nasdaq Extension. The Stock Is Rising.


IBD

by ED CARSON

12/09/2024


https://www.investors.com/news/technology/super-micro-wins-nasdaq-extension-smci-stock/?src=A00220


Super Micr
NVDA SMCI
glenn1919 glenn1919 7 minutes ago
CCLD..............................https://stockcharts.com/h-sc/ui?s=CCLD&p=W&b=5&g=0&id=p86431144783
CCLD
FLA FLA 7 minutes ago
$BDPTD .105 ^16%
BDPTD